figshare
Browse
igas_a_1482956_sm6628.docx (20.27 kB)

The sensitivity of fecal calprotectin in predicting deep remission in ulcerative colitis

Download (20.27 kB)
journal contribution
posted on 2018-07-03, 10:33 authored by Katrine Carlsen, Lene Buhl Riis, Henriette Elsberg, Louise Maagaard, Tine Thorkilgaard, Sveinung Wergeland Sørbye, Christian Jakobsen, Vibeke Wewer, Jon Florholmen, Rasmus Goll, Pia Munkholm

Background: Mucosal healing is proposed as treat-to-target in ulcerative colitis (UC), even though the definition of mucosal healing remains contested as it has been suggested to be assessed by either endoscopy, histology or both. However, all definitions require an endoscopic evaluation of the mucosa. As endoscopies are invasive and uncomfortable to the patient we aimed to calibrate noninvasive predictors of mucosal inflammatory status defined by both endoscopy and histology.

Methods: UC patients (n = 106) undergoing a sigmoid-/colonoscopy were prospectively included. Feces (fecal calprotectin, FC), blood samples (hemoglobin, C-reactive protein, orosomucoid, erythrocyte sedimentation rate, albumin) and symptom scores (Simple Clinical Colitis Activity Index, SSCAI) were collected and analyzed. The colonic mucosa was assessed by the Mayo endoscopic sub score and biopsies were obtained for a histologic grading by Geboes score. Predictive cutoff values were analyzed by receiver operating characteristics (ROC). A combined endoscopic and histologic assessment defined deep remission (Mayo =0 and Geboes ≤1) and activity (Mayo ≥2 and Geboes >3).

Results: Only FC showed a significant ROC curve (p < .05). We suggest FC (mg/kg) cutoffs for detection of following: Deep remission: FC ≤25; Indeterminate: FC 25-230 – an endoscopy is recommended if a comprehensive status of both endoscopic and histologic assessed activity is needed; Active disease: FC >230. The complete ROC data is presented, enabling extraction of an FC cutoff value’s sensitivity and specificity.

Conclusions: FC predicts endoscopic and histologic assessed deep remission and inflammatory activity of colon mucosa. Neither the markers in blood nor the SCCAI performed significant ROC results.

Funding

This work was supported by CALPRO A/S Norway, Tillotts Pharma Denmark, Capital Region Denmark, Herlev and Gentofte Hospital Research Foundation, Denmark and Foundation of Gastroenterology, University Hospital of North Norway, Tromsø, Norway.

History